Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Adalimumab].

Daisuke Goto1, Takayuki Sumida

  • 1Department of Internal Medicine, University of Tsukuba.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 4, 2003
PubMed
Summary
This summary is machine-generated.

Adalimumab, a fully human anti-tumor necrosis factor-alpha antibody, effectively treats rheumatoid arthritis (RA) symptoms and protects joints. Combined with methotrexate, it offers superior efficacy for patients with RA.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysmenorrhea patients' experience with work productivity impact and treatment in Japan.

BMC women's health·2026
Same author

Biomarker-based clustering identifies distinct pulmonary function trajectories in early systemic sclerosis.

Frontiers in immunology·2026
Same author

Recent increase in N<sub>2</sub>O growth rate (2013-2023) mainly due to increase of nitrogen-fertiliser and manure use in the Northern Tropics and Southern Landmass.

Geoscience letters·2026
Same author

Wet deposition modeling and behavior analysis of <sup>137</sup>Cs aerosols using ten observation-based continuous size distributions following the Fukushima accident.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Nature communications·2026
Same author

Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod.

Clinical and experimental immunology·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Immunology
  • Rheumatology

Context:

  • Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and pain.
  • Anti-tumor necrosis factor (TNF)-alpha therapies have shown success in managing RA symptoms.

Purpose:

  • To evaluate the efficacy and therapeutic potential of Adalimumab (D2E7), a fully human anti-TNF-alpha monoclonal antibody, in treating rheumatoid arthritis.
  • To assess the combined therapy of Adalimumab with methotrexate (MTX) for RA patients inadequately controlled by MTX alone.

Summary:

  • Adalimumab is a human IgG1 monoclonal antibody targeting TNF-alpha, administered subcutaneously at 1 mg/kg biweekly.
  • Therapeutic effects manifest within 24 hours to one week, with maximum response in one to two weeks.
  • Adalimumab treatment controls radiographic progression and reduces serum matrix metalloproteinase (MMP)-1 and MMP-3 levels in RA patients.

Related Experiment Videos

Impact:

  • Adalimumab demonstrates low immunogenicity and significant therapeutic potential compared to other anti-TNF-alpha agents.
  • Combined Adalimumab and methotrexate therapy provides superior symptom control and joint protection for RA patients.
  • Adalimumab treatment is poised to establish a new standard of care for rheumatoid arthritis management.